Connect with us:

Facebook Twitter RSS

News & Updates

19 Sep 2012

Personalised medicine promises radical improvements to healthcare in Europe

On Tuesday 18th September, Nessa Childers, MEP hosted the launch of the Manifesto of the European Alliance for Personalised Medicine in the European Parliament.

The Manifesto sets out both the opportunities and challenges of 'a targeted approach to the prevention, diagnosis and treatment of disease based on an individual’s specific profile' - what is known as personalised medicine.

Currently available treatments for disease have revolutionised health in Europe and beyond, but science has now brought healthcare to the brink of another major evolution.

By a combination of molecular medicine and computer technology, it is becoming possible for screening of patients, early treatment, or prevention to be calibrated precisely, to deliver with maximum effectiveness. With personalised medicine, healthcare services will ensure the right intervention to the right patient at the right time - improving patient outcomes, reducing the likelihood of adverse events, and cutting down unnecessary treatments.
And the precision that personalised medicine will bring creates good prospects for better use of resources. As the demand for healthcare rises and public financing comes under greater strain, personalised medicine can play a part in getting maximum value for spending on health.

The shift towards personalised medicine has already started in fields such as cancer and blood diseases, and new products are being designed to match the approach.
Conditions must be right

But for personalised medicine to deliver on its potential over coming years, the conditions will have to be right. Regulation needs adapting, research needs encouragement, new approaches are needed in assessing the value of personalised medicines, and training of healthcare professionals and awareness among patients and the public need to be boosted.

To catalyse the necessary changes, the European Alliance for Personalised Medicine (EAPM) was created earlier this year. It brings together a wide range of stakeholders, including healthcare providers, payers, industry, regulators, disease specialists, and patients, to promote contact across the many disciplines that contribute to personalised medicine, and to help forge a common approach.


The EAPM Manifesto sets out the requirements to take advantage of the opportunities, which include:

• Adapting the authorisation procedures for medicines to take account of the innovative clinical trial designs that personalised medicine will depend on.

• Wider coordination on research in Europe through Horizon 2020, with better access to information for researchers, doctors, pharmacists and patients.

• High-quality molecular testing facilities in Europe.

• Closer regulatory links between diagnostics and treatment.

• Rules on data protection that safeguard privacy while permitting scientific sharing of data.

• Reimbursement of personalised medicines on the basis of their added value to healthcare systems.

• Multi-disciplinary training for healthcare professionals in the new approaches of personalised medicine.

• Wider awareness among patients and the public of the rationale and potential of personalised medicine.

Nessa Childers, MEP said "Europe must not miss out on this opportunity to improve patient care - as well as to make healthcare more precise and effective. But to realise the potential, it is essential for everyone involved, including policy makers and regulators to come together now to create the conditions on which the success of personalised medicine will depend. I welcome the support of the Cypriot Presidency and their work on this issue and look forward to working with the European Commission and the forthcoming Irish Presidency to ensure that this issue remains on the political agenda'.

John Bowis, Chair of EAPM, said: "The future of healthcare lies in a more personalised approach with a focus not only on a person’s biological make-up but also on environmental and lifestyle factors. Personalised medicine offers a chance for dramatically improved treatments and reduces the likelihood of adverse events for patients. However like any innovation it brings challenges to current systems and attitudes, and today we have sought to identify the priorities for policy makers in Europe to meet these challenges."

More publications

14 Dec 2016: Preserving fertility in girls and young women with cancer “haphazard” say experts 23 Dec 2015: 'Hematological Malignancies: from Mechanisms to Therapy' symposium - March 9/12, 2016 - Milan 02 Dec 2015: European cancer centres finally united in long-term collaborative partnerships 19 Nov 2015: SiRIC-Curie Call for translational research group leaders, Paris, France 20 Oct 2015: IARC Fellowships for Cancer Research 03 Aug 2015: Optimizing sharing of hospital biobank samples: new EurocanPlatform paper published in Science Translational Medicine 17 Jul 2015: 3rd EurocanPlatform Summer School in Translational Cancer Research: Portugal, 12 – 16 October 2015 17 Jul 2015: NCT Heidelberg School of Oncology Fellowship Program in Translational Cancer Research - Call for applications 01 Jul 2015: EurocanPlatform project engages directly with patient groups at ECPC AGM 19 Jun 2015: EurocanPlatform Translational Research Course 12th - 16th October - Save the Date! 13 May 2015: Catch up on all the latest from the EurocanPlatform project in the May 2015 Newsletter 14 Apr 2015: New EurocanPlatform paper published in PLOS One 31 Mar 2015: Launch of personalised medicine survey: Literacy among healthcare professionals 30 Mar 2015: OECI Cancer Days 2015 in Porto, Portugal 10 Mar 2015: Workshop on circulating biomarkers in cancer 19 Feb 2015: Meeting report from the second EurocanPlatform summer school on translational cancer research published in ecancermedicalscience 27 Jan 2015: The January 2015 Newsletter is here! 21 Jan 2015: Most types of cancer not due to “bad luck”, says IARC 06 Jan 2015: Brand new videos available from the 2nd Translational Research Course 08 Dec 2014: New conference report for the EurocanPlatform Chemoprevention Meeting published in ecancermedicalscience 20 Nov 2014: The November 2014 Newsletter is here! 13 Nov 2014: IARC/WHO Fellowships 05 Nov 2014: Research course on circulating tumor cells (CTC) at the Karolinska Institute 28 Oct 2014: Eighth Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice 03 Oct 2014: Core values for a new cancer culture: six centres create Cancer Core Europe 01 Sep 2014: EurocanPlatform paper published in the Journal of Oncology Practice 18 Aug 2014: 4th Annual meeting of EurocanPlatform project, October 25-26th 2014 04 Aug 2014: EurocanPlatform Translational Cancer Research Summer Course, Portugal, October 20-24, 2014 31 Jul 2014: The Summer 2014 Newsletter is here! 18 Jun 2014: Role for an experienced scientist available at the Curie Institute 20 May 2014: New science policy paper published in Molecular Oncology 19 Feb 2014: Workshop on "Tissue-based Biomarkers for Advancement of Personalized Cancer Treatment" 21 Jan 2014: The second Advanced Lecture Course on Translational Cancer Research 21 Jan 2014: OECI and ECPC - How Uniform Is Cancer Care? February 18th 2014 31 Oct 2013: FDA pulls ponatinib approval due to blood clots and narrowing of blood vessels 22 Oct 2013: Publications from within EurocanPlatform - Year 2 09 Oct 2013: IARC: Postdoctoral fellowships for training in cancer research 12 Sep 2013: VHIO-Fritz Bender Foundation joint International Symposium 13 Aug 2013: HPV vaccine could also prevent oropharyngeal cancer, says IARC 13 Aug 2013: New ECPC Board of Directors 11 Jun 2013: EAPM Members Update: Discussion on the Data Protection Legislation 21 May 2013: Growing call to abandon impact factors 29 Apr 2013: New partnership between IARC and CRI to spur cancer research in Thailand and across South-East Asia 11 Apr 2013: OECI 2013 Oncology Days - including EurocanPlatform Session 08 Mar 2013: Spreading the cancer prevention message in Sierra Leone 25 Feb 2013: EAPM: Access to health data is essential for the development of new treatments 20 Feb 2013: Access to health data is essential for the development of new treatments, says European Alliance of Personalised Medicine 23 Jan 2013: Course in cancer genomics at EBI 26 Oct 2012: Scientists discover potential new 'roots' of breast cancer